Prognosis

Introducing the Anbio AF-100S: A Small, Yet Powerful Handheld Analyzer for Rapid, Point-of-Care Testing

Retrieved on: 
Friday, July 14, 2023
Antigen, FIA, Enzyme, Ambulance, Prognosis, Infection, Antibody, Hormone, Patient, POC, Lithium, Medical imaging

Anbio's AF-100S FIA Solution is a handheld point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes.

Key Points: 
  • Anbio's AF-100S FIA Solution is a handheld point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes.
  • The Anbio AF-100S FIA Solution is a powerful tool that can help healthcare professionals provide better care for their patients.
  • High throughput: The analyzer can process up to 240 tests per hour, making it ideal for high-volume settings.
  • Easy-to-use interface: The analyzer features a large color touch screen and a user-friendly interface that makes it easy to operate.

This Week in Health News: 10 Stories You Need to See

Retrieved on: 
Friday, July 14, 2023
Survival, Database, PR Newswire, Quality of life, Research, Subject-matter expert, Prognosis, Patient, News, PHM, Related, Doctor of Philosophy, Geography, Publishing

NEW YORK, July 14, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • We're proud we could help this patient access an emerging treatment at a time his prognosis was poor, and his options were otherwise limited."
  • In addition to these popular releases, several must-read earnings reports crossed the wire this week, including the quarterly results for Harbour BioMed .
  • These are just a few of the recent press releases that consumers and the media should know about.
  • To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists .

Young-onset Alzheimer’s can be diagnosed from as early as 30 – and the symptoms are often different

Retrieved on: 
Thursday, July 13, 2023
People, Learning, Depression, Interview, Awareness, Genetics, Anxiety, Health care, Chocolate, PSEN2, Deficit spending, Prognosis, Brain, Research, Risk, Vegetable, Life expectancy, Dementia, PSEN1, Time, Traumatic brain injury, Amnesia, Diagnosis, APP, Gene, Memory, Hippocampus, Disease, Residential care, Medical imaging, Copper, Birth control, Nursing, Pharmaceutical industry, Dietary supplement

But around 3.9 million people worldwide aged 30-64 live with young-onset Alzheimer’s disease – a form of dementia in which symptoms appear before the age of 65.

Key Points: 
  • But around 3.9 million people worldwide aged 30-64 live with young-onset Alzheimer’s disease – a form of dementia in which symptoms appear before the age of 65.
  • English journalist and broadcaster Fiona Phillips, 62, recently revealed that she’d been diagnosed with it.
  • First, symptoms begin much earlier – as young as 30 in some rare cases, though it’s typically diagnosed between the ages of 50-64.
  • Within the brain itself, young-onset Alzheimer’s disease causes similar chemical changes as those in late-onset Alzheimer’s.

Why it happens

    • For example, poor levels of cardiovascular fitness and lower cognitive ability in early adulthood have been linked to an eight-fold increased risk of developing young-onset Alzheimer’s.
    • One aspect experts are clear on is that genetics play a role in about one in ten cases of young-onset Alzheimer’s disease.
    • Growing evidence suggests there may also be a link between traumatic brain injury and young-onset Alzheimer’s disease.

What can people do?

    • But in the US, two therapies have been approved which may slow the progression of symptoms.
    • However, these were only tested on people with late-onset Alzheimer’s disease, so it’s uncertain if they will have as distinct of an effect.
    • An Italian study found that people who consumed high levels of vegetables, dry fruits and chocolate appeared to have lower risk.

AI might eventually be an extinction threat, but it poses more pressing risks

Retrieved on: 
Tuesday, July 11, 2023
Learning, Technology, Unemployment, Human, Problem solving, Workplace, Identity theft, Survival, ChatGPT, Intelligence, Prognosis, Medicine, Research, Crime, Instinct, Computer, Photography, Student, Risk, Hearing, Artificial intelligence, Knowledge, Diagnosis, AI, Robotics, Health, Consciousness, Automation, Medical device, Management, Customer service, Mobile phone

But whatever you think of such warnings, an existential threat to humanity is likely to be a threat only in the longer term.

Key Points: 
  • But whatever you think of such warnings, an existential threat to humanity is likely to be a threat only in the longer term.
  • This is something I’ve been considering since 1997, when I wrote my first artificial intelligence paper on neural networks .
  • Our aim was to develop an intelligent manufacturing machine that is more capable than humans at detecting faults during machining operations.
  • It’s unlikely that AI systems will be able to produce novel artistic works in the short to medium term.
  • Other fields that could eventually depend on AI include market data analysis, investment decisions and computer programming.

Bad education?

    • Perhaps a better approach would be to modify and enhance how we teach and assess the outcomes of learning.
    • Making education more focused on practical skills and the implementation of knowledge in problem solving could ensure a deeper understanding on the part of students.
    • AI could be used for guidance, in much the same way we currently use calculators, to help enrich people’s knowledge.
    • However, we have assumed up until now that AI systems work as designed to provide accurate information.
    • As such, it might stop being merely a tool to support us and become an entity in its own right.

Innovative treatment for prostate cancer shows long term success

Retrieved on: 
Tuesday, July 11, 2023
Male, Prostate Cancer Foundation, University, Therapy, Prostate cancer, Survival, Cancer, Quality of life, Prognosis, Research, Nuclear medicine, University of Frankfurt, Doctor of Philosophy, Patient, American Cancer Society, FDA, Disease, Medical imaging, Pharmaceutical industry, Frontiers, MD, PHM

LOS ANGELES, July 11, 2023 /PRNewswire/ -- PHM announces the publication of a case report summarizing a patient's complete response to an innovative treatment for prostate cancer. PHM is a clinically and scientifically sophisticated healthcare navigation company that solves complex healthcare problems to help individuals get well and stay well.

Key Points: 
  • LOS ANGELES, July 11, 2023 /PRNewswire/ -- PHM announces the publication of a case report summarizing a patient's complete response to an innovative treatment for prostate cancer.
  • Despite decades of research and multiple treatment options, prostate cancer remains the second leading cause of cancer death in men in the U.S. according to the American Cancer Society, with a new case being diagnosed every three minutes, per the Prostate Cancer Foundation.
  • "This case is a testament to the remarkable impact this treatment can have for metastatic prostate cancer patients.
  • It got smaller with each subsequent treatment, and after the fourth treatment he couldn't see any remaining disease."

AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer

Retrieved on: 
Tuesday, July 11, 2023
ATAC, Breast cancer, Cancer, OTCQB, Royal Marsden Hospital, Woman, Prognosis, Research, Exact sciences, The Royal Marsden NHS Foundation Trust, Patient, Risk, Knowledge, IEO, Recurrence, Pharmaceutical industry, Medical imaging, PHOENIX

This important milestone will support the company’s strategic vision following positive results from transATAC study where StemPrintER assay outperformed the current market leader in risk of recurrence testing for women with early stage breast cancer.

Key Points: 
  • This important milestone will support the company’s strategic vision following positive results from transATAC study where StemPrintER assay outperformed the current market leader in risk of recurrence testing for women with early stage breast cancer.
  • Beyond this agreement, AccuStem intends to work closely with the IEO on additional proprietary cancer assays leveraging StemPrintER technology.
  • The pivotal TransATAC study has been used to evaluate many of the commonly used breast cancer risk scoring assays, including the market leading OncotypeDX.
  • AccuStem plans to launch clinical studies to evaluate StemPrintER’s ability to determine the most effective surgical approach for women with early stage invasive breast cancer.

Global Stem Cell Market Projected to Reach $14 Bn by 2028: Ken Research

Retrieved on: 
Tuesday, July 11, 2023
Non-communicable disease, Entry, Diabetes, Health care, COVID-19, Immune tolerance, Ageing, Prognosis, COVID, KSA, Radiology, Government, Market, Transplant, Dermatology, Privatization, Collection, Patient, Conditional sentence, Growth, Diagnosis, Pharmaceutical industry, Endocrinology

Related Report by Ken Research: –

Key Points: 
  • Related Report by Ken Research: –
    According to Ken Research estimates, the Market Size of Global Stem Cell Banking has shown increasing trend from 2017 to 2022.
  • Placental stem cells are expected to dominate the global stem cell banking market by source due to high immune tolerance which make them a promising option for transplantation and other therapeutic applications.
  • The major market players are focusing on R&D activities to introduce new stem cell therapies in the market.
  • KSA Health Tech Market Outlook to 2027 Driven by Strong Government Initiatives, Technological Advancements and Entry of New Market Players
    According to Ken Research estimates, the Market Size of KSA Health Tech Market has shown increasing trend from 2017 to 2022.

Shineco Subsidiary Receives Marketing Approval from China’s Regulatory Body for its Cardiac 5-Minute Test

Retrieved on: 
Monday, July 10, 2023
Marketing, SISI, ECG, Splenic infarction, Prognosis, Temperature, Hospital, Patient, Collection, Myoglobin, AMI, Distribution, National Medical Products Administration, Diagnosis, Cardiology, Transport, FDA, SATRO-ECG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Heart, Food, NMPA, Medical device

BEIJING, July 10, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of technologically advanced healthcare products and services, announced today that on June 21, 2023, Changzhou Biowin Pharmaceutical Co., Ltd., a majority-owned subsidiary of the Company ("Biowin"), received marketing and distribution approval for its Cardiac 5-Minute Test from the Jiangsu Bureau of the National Medical Products Administration (“NMPA"), which is China’s regulatory equivalent of the U.S. Food and Drug Administration (FDA). The effective date for the diagnostic medical product’s registration with the NMPA is June 21, 2023, and it shall remain valid for five years through June 20, 2028.

Key Points: 
  • The Cardiac 5-Minute Test is a combination test of three major cardiac markers and can detect cardiac troponin I, myoglobin, and heart fatty acid binding protein for the clinical diagnosis of acute myocardial infarction (“AMI”) in one test.
  • "We are very glad to have received marketing approval for our Cardiac 5-Minute Test from the NMPA.
  • We believe that the regulatory approval of our Cardiac 5-Minute Test will ultimately lead to substantial profitability for the Company,” concluded Dr. Liu, CEO of Biowin.
  • We believe that the Cardiac 5-Minute Test will have a wide range of point-of-service administration including hospitals, emergency rooms, cardiology departments, and doctor’s offices.

BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration

Retrieved on: 
Friday, July 7, 2023
Neuroprotection, Gordon Research Conferences, Therapy, Brainstorm, AFL, Prognosis, Doctor of Philosophy, Gordon, Plasma, Plasma protein binding, HIV disease progression rates, Patient, Knowledge, Poster, FDA, ALS, Conference, Neuroinflammation, Disease, Pharmaceutical industry

NEW YORK, July 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week presented new biomarker data from the Phase 3 trial of its late-stage investigational ALS treatment, NurOwn at the 2023 ALS and Related Motor Neuron Diseases Gordon Research Conference. These data show that treatment with NurOwn significantly elevated markers of neuroprotection and lowered markers of neuroinflammation and neurodegeneration, including neurofilament light (NfL) over time compared to placebo in all trial participants.

Key Points: 
  • NEW YORK, July 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week presented new biomarker data from the Phase 3 trial of its late-stage investigational ALS treatment, NurOwn at the 2023 ALS and Related Motor Neuron Diseases Gordon Research Conference .
  • These data show that treatment with NurOwn significantly elevated markers of neuroprotection and lowered markers of neuroinflammation and neurodegeneration, including neurofilament light (NfL) over time compared to placebo in all trial participants.
  • It is believed that reductions in plasma NfL are reasonably likely to predict clinical benefit in ALS.
  • "The data we presented at the Gordon Research Conference show that it is equally important to examine biomarker data, particularly neurofilament light, which is a predictor of disease progression.

Global Oncology Biomarkers Market Report 2023: Increasing Use of Biomarkers in Drug Discovery and Development Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 5, 2023
Biotechnology, Health, Oncology, Prevalence, Clinical trial, Cancer, Prognosis, Research, Biomarker, Investment, Patient, Medicine, Growth, Diagnosis, Environment, Medical imaging, Pharmaceutical industry

The increasing role of biomarkers in clinical diagnostics, precision medicine, and clinical trial management supports growth in this market.

Key Points: 
  • The increasing role of biomarkers in clinical diagnostics, precision medicine, and clinical trial management supports growth in this market.
  • The report also includes an analysis of leading and emerging competitors in the current worldwide oncology biomarkers market.
  • Once these biomarkers are validated and subsequently enter clinical and research applications, the oncology biomarkers market is expected to grow significantly.
  • This market is expected to reach $14.2 billion in 2028, growing at a CAGR of 16.6% through the forecast period.